Welcome to our dedicated page for Sutro Biopharma news (Ticker: STRO), a resource for investors and traders seeking the latest updates and insights on Sutro Biopharma stock.
Sutro Biopharma, Inc. (NASDAQ: STRO) is a clinical-stage oncology company developing next-generation antibody-drug conjugates (ADCs) using a proprietary cell-free platform. The STRO news page on Stock Titan aggregates company announcements, scientific updates, and regulatory disclosures so readers can follow how Sutro’s ADC pipeline and corporate strategy evolve over time.
News about Sutro frequently covers pipeline milestones, such as the initiation of a Phase 1 trial for STRO-004, a tissue factor–targeting exatecan ADC in TF-expressing solid tumors, and preclinical progress for programs like STRO-006 and the dual-payload candidate STRO-227. The company also issues updates on collaborations, including its work with Astellas on dual-payload immunostimulatory ADCs, and presentations at major scientific meetings like the World ADC Conference and the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Investors and observers will find corporate and financial communications here as well, including quarterly financial results, details of organizational restructuring aimed at extending the company’s cash runway, and information about actions related to its Nasdaq listing status, such as the 1-for-10 reverse stock split and subsequent confirmation of regained compliance with the minimum bid price requirement.
In addition, Sutro regularly announces participation in healthcare and investor conferences, virtual R&D days, and other events where management discusses the ADC platform, single- and dual-payload programs, and near- and long-term priorities. Bookmark this page to access a consolidated view of Sutro Biopharma’s latest press releases, scientific highlights, and market-facing updates related to its oncology-focused ADC pipeline.
Sutro Biopharma and BioNova Pharmaceuticals have announced an option agreement for the development and commercialization of STRO-001, a CD74-targeting ADC, in Greater China. BioNova will pay Sutro an initial $4 million and potential milestone payments totaling up to $200 million. Sutro maintains global rights outside Greater China. The collaboration aims to address unmet medical needs in hematologic cancers, with BioNova committed to advancing STRO-001 through clinical development and regulatory approval. Sutro will receive tiered royalties based on sales in the region.
Sutro Biopharma (NASDAQ: STRO) announced on Sept 30, 2021, an extension of its research term for the cytokine derivative program with Merck for an additional two years, aimed at completing preclinical research for a second candidate. Sutro is eligible for up to $10 million from this extension. The collaboration leverages Sutro's proprietary protein engineering platforms, XpressCF® and XpressCF+™, and has previously resulted in milestone payments of $5 million and $15 million for earlier collaborations. The ongoing research could lead to innovative cancer treatments.
Sutro Biopharma announced on September 15, 2021, that its Compensation Committee granted restricted stock units (RSUs) of 150,000 shares and stock options for 145,000 shares to three new employees. These grants were part of an inducement to join Sutro and comply with Nasdaq rules. The RSUs will vest annually over four years, while stock options will vest annually and monthly thereafter, also over four years. Sutro specializes in developing next-generation cancer therapeutics through its protein engineering platforms, advancing multiple ADC candidates in clinical trials.
Sutro Biopharma (NASDAQ: STRO) announced the addition of two key executives, Nicole M. Chieffo and Werner Rubas, to its leadership team. Chieffo, with over 25 years in clinical operations, previously held senior roles at Janssen Pharmaceuticals, leading to successful drug approvals. Rubas brings 30 years of experience, most recently as Executive Director at Nektar Therapeutics. Chief Medical Officer Arturo Molina and President of Research Trevor Hallam highlighted the expertise these leaders bring to advance Sutro's pipeline. The company focuses on developing cancer therapeutics, including its ADCs STRO-001 and STRO-002.
Sutro Biopharma (NASDAQ: STRO) announced that CEO Bill Newell will participate in the 2021 Wells Fargo Securities Healthcare Conference via a virtual fireside chat on September 9 at 3:20 p.m. ET. A live webcast will be available on Sutro's website, with archived replays accessible for 30 days post-event.
Sutro specializes in precise protein engineering to develop innovative cancer therapeutics, with candidates like STRO-001 and STRO-002 in clinical trials.
Sutro Biopharma (NASDAQ: STRO) announced that the FDA has granted Fast Track designation for STRO-002, an antibody-drug conjugate targeting the folate receptor alpha, aimed at treating patients with platinum-resistant ovarian cancer. This designation allows for more frequent FDA interactions, potentially accelerating clinical development. Preliminary studies show promising activity and tolerability of STRO-002. The ongoing Phase 1 trial has completed dose escalation, with enrollment in the expansion cohort continuing in the US and Spain.
Sutro Biopharma (NASDAQ: STRO) reported its Q2 2021 financial results, showing revenue of $28 million, significantly up from $9.5 million in Q2 2020. Cash and equivalents totaled $283.4 million, down from $326.5 million at year-end 2020, with a runway projected into H2 2023. The company continues to make progress in ADC trials, particularly with STRO-002 for ovarian cancer. Notable partnerships include ongoing collaborations with Merck, Bristol Myers Squibb, and EMD Serono. Operating expenses rose to $37.9 million from $25.9 million year-over-year.
Sutro Biopharma (NASDAQ: STRO) appointed Jane Chung as Chief Commercial Officer, effective August 9, 2021. With over 20 years in the pharmaceutical sector, including as President of AstraZeneca Canada, Chung will lead Sutro's commercial strategy, focusing on oncology communities as the company progresses its clinical programs, including STRO-001 and STRO-002. Sutro also granted Chung 75,000 restricted stock units and 160,000 stock options under its 2021 Equity Inducement Plan. The company aims to transform cancer treatment using its innovative technologies.
Sutro Biopharma (NASDAQ: STRO) announced CEO Bill Newell's participation in the panel "ADCs – Take Me to Your Tumor" at the 12th Annual Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021, at 2:20 p.m. ET. A live webcast will be available on the company's website, along with archived replays for 30 days. Sutro focuses on precise protein engineering for next-generation cancer therapies, with candidates like STRO-001 and STRO-002, currently in clinical trials. The company is committed to improving cancer treatments through innovative drug design.
Sutro Biopharma (NASDAQ: STRO) announced CEO Bill Newell will participate in two virtual investor conferences in June 2021. The details are as follows:
- JMP Securities Life Sciences Conference: June 17, 2021, at 3:30 p.m. ET.
- Raymond James Human Health Innovations Conference: June 23, 2021, at 10:40 a.m. ET.
Access live webcasts on the company's website. Sutro focuses on developing next-generation cancer and autoimmune therapeutics through its proprietary XpressCF® platform.